ERK1 antibody (C-Term)

Catalog No. ABIN967398

Product Details anti-ERK1 Antibody

Target: ERK1 (MAPK3) (Mitogen-Activated Protein Kinase 3 (MAPK3))

Binding Specificity: C-Term

Reactivity: Human, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: This ERK1 antibody is un-conjugated

Application: Western Blotting (WB), Immunoprecipitation (IP)

Brand: BD Pharmingen™

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: C-Terminal Region of ERK1

Clone: G262-118

Isotype: IgG2b

Application Details

Comment:

Related Products: ABIN967389

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C.

References for anti-ERK1 antibody (ABIN967398)

Campos-González, Glenney: "Temperature-dependent tyrosine phosphorylation of microtubule-associated protein kinase in epidermal growth factor-stimulated human fibroblasts." in: Cell regulation, Vol. 2, Issue 8, pp. 663-73, (1992) (PubMed).

Target Details for ERK1

Target: ERK1 (MAPK3) (Mitogen-Activated Protein Kinase 3 (MAPK3))

Alternative Name: ERK1 (MAPK3 Products)

Background: A serine/threonine specific protein kinase, called MAP kinase or more recently ERK1 (extracellular signal regulated kinase) is activated in cells following stimulation with EGF (epidermal growth factor), the PDGF (platelet-derived factor) or insulin. ERK1 has been assayed in vitro for phosphotransferase activity using the microtubule-associated protein (MAP) or myelin basic protein. The mechanism by which MAP kinase becomes activated in growth factor treated cells is thought to involve tyrosine and threonine phosphorylation of the kinase itself. The EGF, PDGF and insulin receptors are known to be tyrosine specific protein kinases and studies have shown that MAP kinase is identical to the p42 protein that earlier studies identified as one of the major tyrosine phosphorylated proteins in transformed or growth factor treated cells. While several isoforms of the p42 protein are known, they are thought to be structurally similar. The G262-118 antibody recognizes human and mouse ERK1. It does not cross-react with ERK2. A synthetic peptide from the C-terminal region of ERK1 was used as immunogen.

Molecular Weight: 44 kDa

Pathways: MAPK Signaling, RTK Signaling, Interferon-gamma Pathway, Fc-epsilon Receptor Signaling Pathway, Neurotrophin Signaling Pathway, Response to Growth Hormone Stimulus, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Hepatitis C, Protein targeting to Nucleus, Toll-Like Receptors Cascades, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, VEGFR1 Specific Signals, S100 Proteins